Immutep Ltd ADR is a biotechnology company headquartered in Sydney, Australia, specializing in the development of innovative immunotherapy treatments for cancer and autoimmune diseases. The firm is advancing its lead product candidates designed to modulate immune responses, thereby enhancing the body's capacity to combat tumors. With a promising pipeline and established strategic partnerships, Immutep aims to transform therapeutic approaches in oncology, positioning itself to capitalize on substantial market opportunities as it moves through various clinical trial phases.